H.C. Wainwright

OncoSec Represents An Undervalued Player With Significant Upside For The Long-Term Investor, Says H.C. Wainwright

In a research note published today, H.C.

Editor Ben Weinberg — September 16, 2014, 1:37 PM EDT

H.C. Wainwright Remains Bullish On Keryx Following Ferric Citrate FDA Approval

In a research report issued today, H.C.

Scott Fields Scott Fields — September 16, 2014, 12:33 PM EDT

H.C. Wainwright Reiterates Buy On United Therapeutics Following Healthcare Conference

In a research report issued Monday, H.C.

Ben Mahaney, Editor — September 15, 2014, 4:10 PM EDT

RXi Pharmaceuticals: A Nearly 40% Sell-Off Creates A Unique Buying Opportunity, Says H.C. Wainwright

In a research report issued yesterday, H.C.

Ben Mahaney, Editor — September 12, 2014, 12:13 PM EDT

H.C. Wainwright Reiterates Buy On Spectrum On The Heels Of Phase 3 Plans For SPI-2012

In a research report issued today, H.C.

Ben Mahaney, Editor — September 12, 2014, 11:54 AM EDT

Wainwright Maintains Buy on Insmed Following NTM Update From The ERS Meeting

In a report issued today, H.C.

Scott Fields Scott Fields — September 8, 2014, 11:40 AM EDT

We Expect THLD Shares To Perform Well Into 2015, Says H.C. Wainwright

In a research report issued today, H.C.

Ben Mahaney, Editor — September 5, 2014, 9:20 AM EDT

H.C. Wainwright Reiterates Buy On Paramount Gold & Silver, Cuts PT To $1.70

In a research note released Tuesday, H.C.

Editor Ben Weinberg — September 2, 2014, 11:07 AM EDT

Wainwright Reiterates Buy On United Therapeutics Following Judge Ruling On Patent

In a research note published today, H.C.

Scott Fields Scott Fields — September 2, 2014, 10:36 AM EDT

H.C. Wainwright Reiterates Buy On EDAP Following 2Q14 Update

In a report issued today, H.C.

Ben Mahaney, Editor — August 28, 2014, 2:28 PM EDT

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts